KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $9.4 million.

  • Vir Biotechnology's Non-Current Deffered Revenue changed N/A to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2023, which is 9713.2% down from last year.
  • As of Q3 2025, Vir Biotechnology's Non-Current Deffered Revenue stood at $9.4 million.
  • Over the past 5 years, Vir Biotechnology's Non-Current Deffered Revenue peaked at $55.5 million during Q2 2021, and registered a low of $1.5 million during Q4 2023.
  • In the last 5 years, Vir Biotechnology's Non-Current Deffered Revenue had a median value of $7.6 million in 2022 and averaged $25.5 million.
  • In the last 5 years, Vir Biotechnology's Non-Current Deffered Revenue surged by 135467.89% in 2021 and then crashed by 9713.2% in 2023.
  • Quarter analysis of 5 years shows Vir Biotechnology's Non-Current Deffered Revenue stood at $3.8 million in 2021, then soared by 1294.68% to $53.2 million in 2022, then tumbled by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then soared by 518.15% to $9.4 million in 2025.
  • Its Non-Current Deffered Revenue stands at $9.4 million for Q3 2025, versus $1.5 million for Q1 2024 and $1.5 million for Q4 2023.